Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment.
High growth potential with excellent balance sheet.
Share Price & News
How has Medical Developments International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MVP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MVP exceeded the Australian Pharmaceuticals industry which returned -8.5% over the past year.
Return vs Market: MVP exceeded the Australian Market which returned -9.4% over the past year.
Price Volatility Vs. Market
How volatile is Medical Developments International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StShareholders Are Thrilled That The Medical Developments International (ASX:MVP) Share Price Increased 170%
1 month ago | Simply Wall StWhy Medical Developments International Limited's (ASX:MVP) CEO Pay Matters To You
3 months ago | Simply Wall StWith A 2.3% Return On Equity, Is Medical Developments International Limited (ASX:MVP) A Quality Stock?
Is Medical Developments International undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MVP (A$7.88) is trading above our estimate of fair value (A$0.46)
Significantly Below Fair Value: MVP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MVP is poor value based on its PE Ratio (451.2x) compared to the Pharmaceuticals industry average (19.2x).
PE vs Market: MVP is poor value based on its PE Ratio (451.2x) compared to the Australian market (15.4x).
Price to Earnings Growth Ratio
PEG Ratio: MVP is poor value based on its PEG Ratio (6.6x)
Price to Book Ratio
PB vs Industry: MVP is overvalued based on its PB Ratio (11.5x) compared to the AU Pharmaceuticals industry average (2.4x).
How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVP's forecast earnings growth (68.1% per year) is above the savings rate (2.3%).
Earnings vs Market: MVP's earnings (68.1% per year) are forecast to grow faster than the Australian market (14.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MVP's revenue (30.8% per year) is forecast to grow faster than the Australian market (4.2% per year).
High Growth Revenue: MVP's revenue (30.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MVP's Return on Equity is forecast to be low in 3 years time (7.6%).
How has Medical Developments International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MVP has a high level of non-cash earnings.
Growing Profit Margin: MVP's current net profit margins (5.2%) are higher than last year (1.3%).
Past Earnings Growth Analysis
Earnings Trend: MVP's earnings have declined by -12.7% per year over the past 5 years.
Accelerating Growth: MVP's earnings growth over the past year (362.1%) exceeds its 5-year average (-12.7% per year).
Earnings vs Industry: MVP earnings growth over the past year (362.1%) exceeded the Pharmaceuticals industry 28.6%.
Return on Equity
High ROE: MVP's Return on Equity (2.6%) is considered low.
How is Medical Developments International's financial position?
Financial Position Analysis
Short Term Liabilities: MVP's short term assets (A$32.3M) exceed its short term liabilities (A$8.6M).
Long Term Liabilities: MVP's short term assets (A$32.3M) do not cover its long term liabilities (A$34.0M).
Debt to Equity History and Analysis
Debt Level: MVP's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: MVP's debt to equity ratio has reduced from 9.5% to 0.4% over the past 5 years.
Debt Coverage: MVP's debt is well covered by operating cash flow (681.3%).
Interest Coverage: MVP earns more interest than it pays, so coverage of interest payments is not a concern.
What is Medical Developments International's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MVP's dividend (0.51%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.68%).
High Dividend: MVP's dividend (0.51%) is low compared to the top 25% of dividend payers in the Australian market (6.6%).
Stability and Growth of Payments
Stable Dividend: MVP is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: MVP is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MVP is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MVP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Sharman (53yo)
Mr. John Stewart Sharman, M.App.Fin, CA, B Ec, serves as Chief Executive Officer at Universal Biosensors, Inc. since 2020. He serves as Investment Director of CVC Venture Managers Pty Limited. Mr. Sharman ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD428.72K) is below average for companies of similar size in the Australian market ($USD772.90K).
Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.
|Chief Executive Officer||10.08yrs||AU$643.99k||0.0079% A$40.8k|
|CFO & Company Secretary||2.58yrs||AU$249.38k||no data|
|Head of Operations||0.83yr||no data||no data|
|Head of Sales & Marketing||0.83yr||no data||no data|
|Head of Human Resources||0.83yr||no data||no data|
|Chief Scientific Officer||0.83yr||no data||no data|
|Head of Medical Affairs||1.75yrs||no data||no data|
|Head of Regulatory Affairs||1.5yrs||no data||no data|
|Head of Quality||1.33yrs||no data||no data|
|Head of Project Management Office||0.83yr||no data||no data|
Experienced Management: MVP's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|Non-Executive Director||5.42yrs||AU$51.25k||0.40% A$2.1m|
|Non Executive Chairman||16.67yrs||AU$83.33k||13.13% A$67.9m|
|Non-Executive Director||7.5yrs||AU$51.25k||0.061% A$314.1k|
|Non-Executive Director||6.67yrs||AU$51.25k||0.022% A$111.3k|
|Non-Executive Director||no data||no data||no data|
Experienced Board: MVP's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medical Developments International Limited's company bio, employee growth, exchange listings and data sources
- Name: Medical Developments International Limited
- Ticker: MVP
- Exchange: ASX
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$517.113m
- Shares outstanding: 65.62m
- Website: https://www.medicaldev.com
Number of Employees
- Medical Developments International Limited
- 4 Caribbean Drive
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MVP||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 2003|
|MDDV.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 2003|
|MVP||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 2003|
Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment. The company operates in three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in homes, pharmacies, hospitals, medical practices, and aged care facilities; Penthrox, a prescription only medicine for pain relief; medical devices; and various veterinary anesthetic machines to veterinarians. The company operates in Australia, New Zealand, Italy, rest of Europe, the United Kingdom, Canada, the Middle East, South Africa, North America, Rest of Asia, and internationally. Medical Developments International Limited is headquartered in Scoresby, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/29 14:22|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.